News
SOURCE: ELEGEN NEWS
Elegen Launches ENFINIA™ DNA Enhancement for Rapid Synthesis of Highly Complex DNA
Following successful, fully subscribed Early Access and Beta Programs, Elegen’s latest ENFINIA DNA enhancement provides access to very challenging sequences, including long repeats and STRs, GC-rich promoters, enhancers, terminators, ITRs, LTRs and homopolymers.
SOURCE: Fast Company
The World's Most Innovative Companies of 2024
Elegen has been named among the world’s most innovative companies by Fast Co., ranked #2 in Small but Mighty.
SOURCE: The Healthcare Technology Report
The Top 25 Biotechnology Companies of 2024
Elegen has been named among the Top 25 Biotechnology Companies of 2024 by the Healthcare Technology Report.
SOURCE: BioCompare
Improving Cell and Gene Therapy Process Development
Cell and gene therapies (CGT) represent the cutting edge of biotherapeutics, using DNA and life itself as therapeutic agents. CGT process development requires the coordination of many parts, including cells, DNA constructs, and gene delivery vectors. As a key starting material, CGT development requires a constant flow of high-accuracy, long, and complex custom DNA. Elegen is addressing this synthesis bottleneck with its cell-free DNA synthesis process.
SOURCE: SynBioBeta
Health and Medicine News: Elegen Partners with GSK
Exclusive Interview: Elegen CEO Matthew Hill on new collaboration with GSK.
SOURCE: Life Science Success Podcast
Life Science Success Podcast: Cell-free DNA Synthesis of Industry Leading Long and Complex DNA
In this episode of Life Science Success Don Davis interviews guest Matt Hill, founder and CEO of Elegen, a privately-held company based in the San Francisco Bay Area, committed to revolutionizing synthetic biology workflows with an innovative DNA writing technology.
SOURCE: Genetic Engineering News
GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines
Elegen’s ability to produce NGS-verified linear DNA up to 7 kb within a week with error rates as low as 1:70,000 per bp (99.999% per base accuracy) could be an important marker as it tries to establish a leading position in a heated race to deliver what could be the next major medicinal breakthrough.
SOURCE: ELEGEN NEWS
Elegen Announces Multi-Year Collaboration and Licensing Agreement with GSK
GSK has signed a collaboration & licensing agreement to leverage Elegen’s cell-free DNA manufacturing technology in the development of GSK’s vaccines & medicines.
SOURCE: Business Intelligence Group
11 Executives, 47 Companies and 108 Products Win 2024 BIG Innovation Award
Business Intelligence Group Announces the Winners of the 2024 BIG Innovation Awards
SOURCE: Technology Networks
Synthetic DNA Advances Will Catalyze the Next Wave of Biotherapeutic Innovation
Recent innovations in DNA manufacturing are helping eliminate critical bottlenecks to bring new therapies to market faster than ever.
SOURCE: Nature Biotechnology
DNA Writing Technologies Moving Towards Synthetic Genomes
Nature reviews the latest advancements in DNA synthesis and the key challenges the new players like Elegen are quickly overcoming.
SOURCE: Biocompare
Cell Expansion for Cell Therapies
Biocompare recently published on the challenges of scaling cell therapies. Part of this challenge starts UPSTREAM in determining the optimal DNA sequence for expansion–a time-consuming, resource-intensive process.
SOURCE: Drug Discovery World Magazine
Accelerating Biotherapy and Personalized Medicine with Long DNA
Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development.
SOURCE: BIOS Community
BIOS Builders Episode 15
Podcast featuring Matt Hill – Founder & CEO of Elegen
SOURCE: ELEGEN NEWS
Elegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time
DNA lengths of 15,000 base pairs and higher represent twice the length of the Company’s recently launched flagship product, ENFINIA DNA, and industry-leading complexity and turnaround time
SOURCE: ELEGEN NEWS
Elegen Launches New Online Ordering Portal for Rapid, High-Accuracy, Long DNA
Company focuses on ease of use, utility, and speed to increase ENFINIA DNA’s impact on workflow efficiency and productivity.
SOURCE: Forbes
Synthetic Biology Is Set To Explode, But Only Once This Huge Bottleneck Is Gone
Guest author John Cumbers, CEO of SynBioBeta meets with Elegen Founder and CEO, Matthew Hill
SOURCE: Mendelspod
Elegen Pioneers Long DNA Subindustry with CEO, Matt Hill
Mendelspod Podcast Featuring Elegen CEO and Founder, Matthew Hill
SOURCE: GenomeWeb
Synthetic DNA Startup Elegen Gains Traction With Customers, Funders
Note: GenomeWeb Premium Subscription Required
SOURCE: ELEGEN NEWS
Elegen Launches ENFINIA™ DNA
New product delivers up to 7kb of high-accuracy DNA in as fast as 7 days, providing an unparalleled combination of speed, length, and quality to the synthetic biology market
SOURCE: Genetic Engineering News
Enabling the Synthetic Biology Revolution
The team at Elegen knows that when barriers to the fast, accurate, and low-cost synthesis of long DNA fall, biotechnology will be driven by the design-build-test-learn cycle